image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 153.01
-1.11 %
$ 27 B
Market Cap
20.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IQV stock under the worst case scenario is HIDDEN Compared to the current market price of 153 USD, IQVIA Holdings Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IQV stock under the base case scenario is HIDDEN Compared to the current market price of 153 USD, IQVIA Holdings Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IQV stock under the best case scenario is HIDDEN Compared to the current market price of 153 USD, IQVIA Holdings Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IQV

image
$240.0$240.0$230.0$230.0$220.0$220.0$210.0$210.0$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
15.4 B REVENUE
2.81%
2.2 B OPERATING INCOME
11.38%
1.37 B NET INCOME
1.10%
2.72 B OPERATING CASH FLOW
26.38%
-1.44 B INVESTING CASH FLOW
9.92%
-878 M FINANCING CASH FLOW
-129.84%
3.96 B REVENUE
1.59%
626 M OPERATING INCOME
13.82%
437 M NET INCOME
53.33%
885 M OPERATING CASH FLOW
22.75%
-310 M INVESTING CASH FLOW
48.25%
-375 M FINANCING CASH FLOW
-173.72%
Balance Sheet IQVIA Holdings Inc.
image
Current Assets 5.83 B
Cash & Short-Term Investments 1.7 B
Receivables 3.8 B
Other Current Assets 331 M
Non-Current Assets 21.1 B
Long-Term Investments 108 M
PP&E 773 M
Other Non-Current Assets 20.2 B
6.33 %14.11 %2.87 %75.05 %Total Assets$26.9b
Current Liabilities 6.96 B
Accounts Payable 736 M
Short-Term Debt 1.14 B
Other Current Liabilities 5.08 B
Non-Current Liabilities 13.9 B
Long-Term Debt 346 M
Other Non-Current Liabilities 13.5 B
3.53 %5.50 %24.37 %64.94 %Total Liabilities$20.8b
EFFICIENCY
Earnings Waterfall IQVIA Holdings Inc.
image
Revenue 15.4 B
Cost Of Revenue 10 B
Gross Profit 5.38 B
Operating Expenses 3.17 B
Operating Income 2.2 B
Other Expenses 829 M
Net Income 1.37 B
16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b0015b(10b)5b(3b)2b(829m)1bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
34.89% GROSS MARGIN
34.89%
14.29% OPERATING MARGIN
14.29%
8.91% NET MARGIN
8.91%
22.63% ROE
22.63%
5.10% ROA
5.10%
8.56% ROIC
8.56%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IQVIA Holdings Inc.
image
3b3b3b3b2b2b2b2b1b1b500m500m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 1.37 B
Depreciation & Amortization 1.11 B
Capital Expenditures 0
Stock-Based Compensation 206 M
Change in Working Capital 158 M
Others -145 M
Free Cash Flow 2.72 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IQVIA Holdings Inc.
image
Wall Street analysts predict an average 1-year price target for IQV of $260 , with forecasts ranging from a low of $175 to a high of $300 .
IQV Lowest Price Target Wall Street Target
175 USD 14.62%
IQV Average Price Target Wall Street Target
260 USD 69.84%
IQV Highest Price Target Wall Street Target
300 USD 96.07%
Price
Max Price Target
Min Price Target
Average Price Target
300300280280260260240240220220200200180180160160140140May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership IQVIA Holdings Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
320 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
256 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation. zacks.com - 3 weeks ago
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors. zacks.com - 1 month ago
Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation UPPER NYACK, N.Y.--(BUSINESS WIRE)--When pharmacists can't give adult vaccinations, millions of people go without them. businesswire.com - 1 month ago
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 month ago
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio. businesswire.com - 1 month ago
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead. businesswire.com - 1 month ago
IQVIA Releases 2024 Sustainability Report RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr. businesswire.com - 1 month ago
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management. zacks.com - 2 months ago
IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years. seekingalpha.com - 2 months ago
IQVIA (IQV) International Revenue Performance Explored Explore how IQVIA's (IQV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. zacks.com - 2 months ago
IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y Growth in the Research and Development, and Technology and Analytics segments aids IQV's top line in the fourth quarter of 2024. zacks.com - 2 months ago
IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript IQVIA Holdings Inc. (NYSE:IQV ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Kerri Joseph – Senior Vice President, Investor Relations and Treasury Ari Bousbib – Chairman and Chief Executive Officer Ron Bruehlman – Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum – Stifel Elizabeth Anderson – Evercore ISI Ann Hynes – Mizuho David Windley – Jefferies Charles Rhyee – TD Cowen Jack Meehan – Nephron Research Michael Ryskin – Bank of America Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 months ago
8. Profile Summary

IQVIA Holdings Inc. IQV

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 27 B
Dividend Yield 0.00%
Description IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Contact 4820 Emperor boulevard, Durham, NC, 27703 https://www.iqvia.com
IPO Date May 9, 2013
Employees 88000
Officers Mr. Bhavik Patel President of Commercial Solutions - IQVIA Ms. Keriann Cherofsky Senior Vice President, Corporate Controller & Chief Accounting Officer Ms. Trudy Stein Chief Human Resources Officer & Executive Vice President Mr. Eric M. Sherbet J.D. Executive Vice President, General Counsel & Secretary Mr. W. Richard Staub III President of Research & Development Solutions Dr. Jeffrey A. Spaeder M.D. Senior Vice President, Global Chief Medical & Scientific Officer Kerri Joseph SVice President of Investment Relation & Treasury Dr. Cynthia L. Verst President of Design & Delivery Innovation Mr. Ari Bousbib Chief Executive Officer & Chairman Mr. Ronald E. Bruehlman Executive Vice President & Chief Financial Officer